Hermetica Superfood Encyclopedia
The Short Answer
Asiaticoside is a triterpenoid saponin derived from Centella asiatica that promotes tissue repair by stimulating collagen type I synthesis and activating angiogenic signaling pathways. It also modulates oxidative stress responses through upregulation of NRF2-driven antioxidant gene expression.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordasiaticoside benefits
Synergy Pairings5
Asiaticoside (Triterpenoid saponin) — botanical close-up
Health Benefits
Origin & History
Natural habitat
Asiaticoside is a triterpenoid saponin with molecular formula C48H78O19, isolated primarily from Centella asiatica (Gotu Kola), a perennial herbaceous plant native to Asian wetlands. It is extracted from C. asiatica leaves and stems using aqueous or solvent methods, yielding standardized extracts rich in triterpenes including asiaticoside, madecassoside, asiatic acid, and madecassic acid.
“Centella asiatica, the source of asiaticoside, has been used for centuries in Traditional Chinese Medicine, Ayurveda, and Southeast Asian healing systems to treat skin wounds, burns, eczema, and neurological conditions like anxiety and cognitive decline. Traditional preparations focused on aqueous extracts for promoting wound healing, reducing inflammation, and enhancing circulation.”Traditional Medicine
Scientific Research
Human clinical evidence for isolated asiaticoside is extremely limited, with only one Phase 1 crossover trial (n=4) testing C. asiatica extract containing asiaticoside (PMID: 35204098), which confirmed safety and bioavailability but assessed no efficacy outcomes. A systematic review of 109 studies found primarily preclinical data supporting neurological and skin benefits, with sparse human RCTs focused on wound healing rather than isolated asiaticoside.
Preparation & Dosage
Traditional preparation
Clinically studied doses include 500 mg oral asiaticoside achieving plasma levels of 1.50-2.71 ng/mL, and 2-4 g of standardized C. asiatica aqueous extract containing asiaticoside and other triterpenes, which were safe and well-tolerated. No specific standardization percentages for asiaticoside content were detailed in human studies. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Asiaticoside is a purified triterpenoid saponin compound, not a whole food ingredient, and therefore does not contain macronutrients (protein, fat, carbohydrates), dietary fiber, vitamins, or minerals in any meaningful quantity. As an isolated bioactive molecule, its profile is defined entirely by its chemical structure and pharmacokinetic properties. Molecular weight: 959.14 g/mol. Chemical structure: consists of a triterpene aglycone core (asiatic acid) glycosidically linked to a trisaccharide unit (two rhamnose units and one glucose unit). Typical concentration in Centella asiatica dry leaf extract: 0.1–0.9% by weight, varying by cultivar and growing conditions. In standardized commercial extracts (e.g., TECA, Madecassol), asiaticoside is typically present at 40% concentration alongside madecassoside (~30%), asiatic acid (~30%), and madecassic acid. Oral bioavailability is limited due to its high molecular weight and hydrophilic glycoside structure; it undergoes intestinal hydrolysis to release the aglycone asiatic acid, which is the primary systemically absorbed form. Asiatic acid plasma half-life is approximately 2–3 hours after oral dosing. Topical formulations achieve higher local tissue concentrations relevant to wound-healing applications. No caloric contribution is applicable at therapeutic doses (typically 30–100 mg per day in clinical research contexts).
How It Works
Mechanism of Action
Asiaticoside stimulates fibroblast proliferation and upregulates collagen type I (COL1A1) gene expression, accelerating extracellular matrix remodeling during wound healing. It activates the NRF2 (nuclear factor erythroid 2-related factor 2) transcription pathway, inducing downstream antioxidant enzymes including heme oxygenase-1 (HO-1) and superoxide dismutase (SOD). Additionally, asiaticoside disrupts bacterial cell membrane integrity and has demonstrated synergistic inhibition of efflux pump activity when combined with conventional antibiotics such as ciprofloxacin in vitro.
Clinical Evidence
Human clinical evidence for asiaticoside remains extremely limited; the most notable antioxidant trial enrolled only four participants, making it insufficient to draw reliable conclusions about efficacy or optimal dosing. Preclinical wound-healing data from rodent excision and incision models show statistically significant improvements in tensile strength and collagen deposition compared to controls, but these findings have not been replicated in adequately powered randomized controlled trials. Antibacterial synergy studies are confined to in vitro settings using bacterial cultures, and no human pharmacokinetic trials have established bioavailability benchmarks for oral or topical asiaticoside formulations. Overall, the evidence base is preliminary and largely mechanistic, requiring large-scale human trials before therapeutic claims can be substantiated.
Safety & Interactions
Topical Centella asiatica preparations containing asiaticoside are generally well tolerated, with contact dermatitis reported in a small subset of sensitive individuals. Oral use at higher experimental doses has been associated with hepatotoxic effects in animal studies, and caution is advised in individuals with pre-existing liver conditions or those consuming hepatotoxic drugs. Asiaticoside may theoretically potentiate antibiotic effects due to efflux pump inhibition, which could alter pharmacodynamics of co-administered antimicrobials. Insufficient safety data exist for use during pregnancy or lactation, and avoidance is recommended in these populations until further evidence is available.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
How does asiaticoside promote wound healing?
Asiaticoside stimulates dermal fibroblasts to upregulate COL1A1 gene expression, increasing collagen type I deposition and improving wound tensile strength. It also promotes angiogenesis by enhancing vascular endothelial growth factor (VEGF) signaling, accelerating the formation of new blood vessels needed for tissue repair. These effects have been demonstrated in preclinical rodent wound models but lack confirmation from human clinical trials.
What is the NRF2 pathway and how does asiaticoside activate it?
NRF2 (nuclear factor erythroid 2-related factor 2) is a master transcription factor that, when activated, binds to antioxidant response elements (ARE) in DNA and upregulates cytoprotective enzymes including HO-1, SOD, and glutathione peroxidase. Asiaticoside appears to facilitate NRF2 nuclear translocation by inhibiting its repressor protein KEAP1, thereby amplifying the cell's endogenous antioxidant defense. A preliminary human pilot study (n=4) reported measurable changes in NRF2-related gene expression following supplementation, though the sample size is too small to confirm clinical relevance.
Can asiaticoside be taken with antibiotics?
In vitro studies suggest asiaticoside can inhibit bacterial efflux pumps, which are mechanisms bacteria use to expel antibiotics, potentially enhancing the efficacy of drugs like ciprofloxacin against resistant strains. However, this interaction has not been studied in humans, so no evidence-based dosing protocol exists for combination use. Individuals considering concurrent use should consult a healthcare provider, as altered antibiotic pharmacodynamics could have unpredictable clinical outcomes.
Is asiaticoside safe for long-term use?
Long-term safety data for isolated asiaticoside supplementation in humans is absent from the published literature. Animal studies have indicated dose-dependent hepatotoxicity at elevated oral doses, suggesting the liver is a primary organ of concern with prolonged or high-dose exposure. Topical formulations containing Centella asiatica standardized extracts (which include asiaticoside) have a longer history of use with a relatively favorable safety profile, but systemic oral supplementation warrants medical supervision.
What foods or plants naturally contain asiaticoside?
Asiaticoside is found almost exclusively in Centella asiatica (commonly called gotu kola or Indian pennywort), a herbaceous plant native to Asia, Africa, and parts of Australia. The compound is concentrated in the leaves and stems, and standardized extracts of Centella asiatica are typically titrated to contain 40% asiaticoside alongside related triterpenes such as madecassoside and asiatic acid. Fresh or dried gotu kola leaves consumed in traditional South and Southeast Asian cuisine provide small amounts of asiaticoside, though far lower concentrations than standardized supplement extracts.
What is the difference between asiaticoside and other triterpenoid saponins from Centella asiatica?
Asiaticoside is one of three major triterpenoid saponins found in Centella asiatica, alongside madecassoside and asiatic acid, each with distinct chemical structures and potency profiles. While asiaticoside is the most abundant form and shows strong collagen-promoting effects in preclinical studies, madecassoside exhibits different bioavailability characteristics in human metabolism. Standardized extracts often specify the asiaticoside content because it correlates most strongly with traditional wound-healing applications, though the synergistic effects of all three compounds together remain largely unstudied in humans.
Is asiaticoside safe for pregnant or breastfeeding women?
There is insufficient clinical evidence to establish safety or risk for asiaticoside use during pregnancy and breastfeeding, as human studies in these populations have not been conducted. Traditional use of Centella asiatica in some cultures suggests a history of use, but this does not constitute proof of safety during sensitive periods of fetal development or lactation. Pregnant and breastfeeding women should consult a healthcare provider before supplementing with asiaticoside until adequate safety data becomes available.
How strong is the clinical evidence for asiaticoside's health benefits compared to preclinical research?
Most evidence for asiaticoside comes from laboratory and animal studies demonstrating wound healing and antioxidant effects; however, human clinical trials remain extremely limited, with only preliminary data from a small trial (n=4) examining NRF2 pathway activation. Wound healing claims are based primarily on in vitro and animal models, meaning efficacy in humans has not been definitively established. The gap between preclinical promise and human evidence means asiaticoside should be considered an emerging ingredient with potential rather than a proven therapeutic agent.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w asiaticoside curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
